期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 58, 期 3, 页码 670-680出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201804882
关键词
cancer; immunogenic cell death; immunotherapy; nanoparticles
资金
- National Cancer Institute [U01-CA198989, 1R01CA216436]
- University of Chicago Medicine Comprehensive Cancer Center [NIH CCSG: P30 CA014599]
Cancer immunotherapies that train or stimulate the inherent immunological systems to recognize, attack, and eradicate tumor cells with minimal damage to healthy cells have demonstrated promising clinical responses in recent years. However, most of these immunotherapeutic strategies only benefit a small subset of patients and cause systemic autoimmune side effects in some patients. Immunogenic cell death (ICD)-inducing modalities not only directly kill cancer cells but also induce antitumor immune responses against a broad spectrum of solid tumors. Such strategies for generating vaccine-like functions could be used to stimulate a cold tumor microenvironment to become an immunogenic, hot tumor microenvironment, working in synergy with immunotherapies to increase patient response rates and lead to successful treatment outcomes. This Minireview will focus on nanoparticle-based treatment modalities that can induce and enhance ICD to potentiate cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据